Petros Pharma Changes Certifying Accountant, Effective Jan 8
Ticker: PTPI · Form: 8-K · Filed: Jan 12, 2024 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Jan 12, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: auditor-change, corporate-governance, 8-K
TL;DR
**Petros Pharma just swapped auditors, keep an eye on their next financials.**
AI Summary
Petros Pharmaceuticals, Inc. (PTPI) filed an 8-K on January 12, 2024, reporting a change in its certifying accountant, effective January 8, 2024. This means the company is switching the accounting firm responsible for auditing its financial statements. For investors, this change is important because the auditor provides an independent check on the company's financial health, and a switch can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.
Why It Matters
A change in auditor can sometimes be a red flag, potentially indicating disagreements over accounting practices or a search for a more lenient auditor, which could impact investor confidence in the company's financial transparency.
Risk Assessment
Risk Level: medium — While not inherently negative, a change in auditor introduces uncertainty and warrants closer scrutiny of future financial reports for any significant accounting shifts.
Analyst Insight
A smart investor would monitor Petros Pharmaceuticals' upcoming financial statements closely for any changes in accounting policies or significant adjustments, and potentially research the new auditing firm's reputation and history.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported
- January 12, 2024 (date) — date the 8-K was filed
- 001-39752 (string) — Commission File Number
- PTPI (string) — Trading Symbol for Common Stock
- The Nasdaq Stock Market LLC (string) — exchange where Common Stock is registered
FAQ
What was the specific event reported in this 8-K filing by Petros Pharmaceuticals, Inc.?
The specific event reported was a 'Changes in Registrant's Certifying Accountant', as detailed under 'ITEM INFORMATION' in the filing.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported occurred on January 8, 2024, as stated under 'Date of Report (Date of earliest event reported): January 8, 2024'.
What is the trading symbol and the exchange where Petros Pharmaceuticals, Inc.'s common stock is registered?
The trading symbol for Petros Pharmaceuticals, Inc.'s Common Stock is PTPI, and it is registered on The Nasdaq Stock Market LLC, according to the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address of Petros Pharmaceuticals, Inc. as listed in the filing?
The business address of Petros Pharmaceuticals, Inc. is 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036, as provided in the 'BUSINESS ADDRESS' section.
What is the purpose of an 8-K filing, as indicated by the form's title?
The form's title 'CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934' indicates that an 8-K is used to report current, material events that shareholders should know about.
Filing Stats: 1,084 words · 4 min read · ~4 pages · Grade level 14.9 · Accepted 2024-01-12 16:32:03
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Marke
Filing Documents
- tm243065d1_8k.htm (8-K) — 28KB
- tm243065d1_ex16-1.htm (EX-16.1) — 3KB
- 0001104659-24-003706.txt ( ) — 204KB
- ptpi-20240108.xsd (EX-101.SCH) — 3KB
- ptpi-20240108_lab.xml (EX-101.LAB) — 33KB
- ptpi-20240108_pre.xml (EX-101.PRE) — 22KB
- tm243065d1_8k_htm.xml (XML) — 3KB
01 Changes in Registrant's Certifying Accountant
Item 4.01 Changes in Registrant's Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On January 8, 2024, the Audit Committee (the "Audit Committee") of the Board of Directors of Petros Pharmaceuticals, Inc. (the "Company") dismissed EisnerAmper LLP ("EisnerAmper") as the Company's independent registered public accounting firm, effective immediately. The reports of EisnerAmper on the Company's consolidated financial statements for the two most recent fiscal years, ended December 31, 2022 and December 31, 2021, did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except as follows: EisnerAmper's report on the consolidated financial statements of the Company as of December 31, 2022 and 2021 and for each of the years then ended, contained a separate paragraph stating, "The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has experienced net losses and negative cash flows from operations since inception that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty." During the two most recent fiscal years, ended December 31, 2022 and December 31, 2021, and the subsequent interim period through January 8, 2024 there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) with EisnerAmper on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EisnerAmper, would have caused EisnerAmper to make reference to the s
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 16.1 Letter dated January 12, 2024 from EisnerAmper LLP to the U.S. Securities and Exchange Commission. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PETROS PHARMACEUTICALS, INC. Date: January 12, 2024 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer